DNA Script

    Founded in 2014 in Paris, DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science. The company is pioneering an alternative to traditional DNA synthesis called enzymatic DNA synthesis (EDS), making this technology accessible to labs with the world’s first benchtop enzymatic synthesis instrument, SYNTAX (TM). By putting DNA synthesis back in the lab, DNA Script is transforming life science research through innovative technology that gives researchers unprecedented autonomy.

    SofinnovaCapital

    The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.

    SofinnovaMD Start

    The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.

    SofinnovaCrossover

    The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.

    SofinnovaIndustrial Biotech

    Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.

    SofinnovaTelethon

    The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.

    Welcome to our new website – a fresh look that represents a new SofinnovaFind out more